[{"id":"eb88bc5b-1f87-4827-bf98-c36dbd9bb4a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02092324","created_at":"2021-01-17T17:18:57.844Z","updated_at":"2024-07-02T16:36:38.667Z","phase":"Phase 2","brief_title":"Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia","source_id_and_acronym":"NCT02092324","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" CSF3R","pipe":" | ","alterations":" CSF3R mutation","tags":["CSF3R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CSF3R mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 11/22/2019","primary_completion_date":" 11/22/2019","study_txt":" Completion: 01/24/2020","study_completion_date":" 01/24/2020","last_update_posted":"2020-11-16"}]